AHA again urged the Food and Drug Administration today to allow health system pharmacies to distribute compounded products to other system facilities located more than one mile away. “The AHA is concerned that the one-mile radius limitation [included in draft guidance last year] is not workable for many hospitals and health systems that have centralized their sterile compounding activities in a single location and distribute compounded products to their other system facilities located more than one mile away,” wrote Ashley Thompson, AHA senior vice president for public policy analysis and development, responding to the agency’s request for information on regulatory flexibilities and efficiencies. Instead of the one-mile limit, AHA recommends that the agency allow hospitals and health systems to use the beyond-use date timeframes contained in United States Pharmacopoeia Chapters 797 and 800. AHA also recommended greater FDA oversight of medical device cybersecurity. “We recommend that the FDA proactively set clear measurable expectations for manufacturers before incidents and play a more active role during cybersecurity attacks.”

Related News Articles

Headline
Health care providers can now apply online for Section 1135 waivers related to the COVID-19 pandemic or other public health emergencies, the Centers for…
Headline
The Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology has posted new FAQs on the information…
Headline
The Department of Health and Human Services today released a final federal strategic plan for health information technology over the next five years.…
Headline
In an interim final rule released today, the Department of Health and Human Services’ Office of the National Coordinator for Health Information Technology…
Headline
AHA and other organizations representing the nation’s clinicians, hospitals, health systems and experts in health informatics and health information management…
Headline
In an effort to reduce regulatory burden, the Food and Drug Administration will not require developers to submit a premarket approval application,…